MedTrace Logo

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

NCT06840002 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-30

No results posted yet for this study

Summary

The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.

Conditions

Interventions

DRUG

SHR-A1811

SHR-A1811.

DRUG

Carboplatin

Carboplatin.

DRUG

Bevacizumab

Bevacizumab.

DRUG

Oxaliplatin for Injection

Oxaliplatin for injection.

DRUG

Paclitaxel injection

Paclitaxel injection.

DRUG

Doxorubicin hydrochloride liposome injection

Doxorubicin hydrochloride liposome injetction.

DRUG

Adebrelimab Injection

Adebrelimab injection.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2026-05-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840002 on ClinicalTrials.gov